Interaction between lifetime captopril treatment and NaCl-sensitive hypertension in spontaneously hypertensive rats and Wistar-Kyoto rats

Journal of Hypertension

Volumn 17, Issue 7, 1999, Pages 983-991

  Fang, Zhiwu ^a   Sripairojthikoon, Wanida ^c   Calhoun, David A ^b   Zhu, Sutao ^b   Berecek, Kathleen H ^b   Wyss, J Michael ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Angiotensin converting enzyme; Circadian rhythm; Neuronal regulation of arterial pressure; Salt sensitivity

Indexed keywords

CAPTOPRIL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; HYPERTENSION; LONG TERM CARE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SALT INTAKE; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0032992142     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917070-00015     Document Type: Article

References (36)

1. 1 Kusaka M, Atarashi K, Matsumoto K, Sumida Y, Matsuura H, Shingu T, et al. Plasma renin activity and norepinephrine as predictors for antihypertensive effects of nifedipine and captopril. Am J Hypertens 1991; 4:735-739.
2. 2 de Jonge A, Knape JT, van Meel JC, Kalkman HO, Wilffert B, Thoolen MJ, et al. Effect of converting enzyme inhibition and angiotensin receptor blockade on the vasoconstriction mediated by alpha 1-and alpha 2-adrenoceptor stimulation in pithed normotensive rats. Naunyn-Schmied Arch Pharmacol 1982; 321:309-313.
3. 3 Muller R, Steffen HM, Weller P, Kugel C, Freiheit T, Krone W. Changes in plasma norepinephrine concentration and thrombocyte alpha 2-adrenoceptor density during long-term antihypertensive therapy with nitrendipine and captopril. J Cardiovasc Pharmacol 1994; 24:429-433.
4. 4 Berecek KH, Swords BH, Lo S, Kirk KA. Effect of angiotensin converting enzyme inhibitors upon brain angiotensin II binding. J Hypertens 1992; 10:545-552.
5. 125I] angiotensin II binding sites in the rat brain: a quantitative autoradiographic study. Neuroscience 1986; 18:837-856.
6. 6 Okuno T, Nagahama S, Lindheimer MD, Oparil S. Attenuation of the development of spontaneous hypertension in rats by chronic central administration of captopril. Hypertension 1983; 5:653-662.
7. 7 Phillips MI, Mann JFE, Haebara H, Hoffman WE, Dietz R, Schelling P, et al. Lowering of hypertension by central saralasin in the absence of plasma renin. Nature 1977; 270:445-447.
8. 8 Unger T, Kaufmann-Buhler I, Scholkens B, Ganten D. Brain converting enzyme inhibition: a possible mechanism for the antihypertensive action of captopril in spontaneously hypertensive rats. Eur J Pharmacol 1981; 70:467-478.
9. 9 Berecek KH, Okuno T, Nagahama T, Oparil S. Altered vascular reactivity and baroreflex sensitivity induced by chronic central administration of captopril in the spontaneously hypertensive rat. Hypertension 1983; 5:689-700.
10. 10 Wu JN, Berecek KH, Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril. Hypertension 1993; 22:139-146.
11. 11 Giudicelli JF, Freslon JL, Richer C. Antihypertensives and the prevention of development of genetic hypertension in the hypertensive SHR rat. Paroi Arterielle 1980; 6:233-237.
12. 12 Harrap SB, Mitchell GA, Casley DJ, Mirakian C, Doyle AE. Angiotensin II, sodium, and cardiovascular hypertrophy in spontaneously hypertensive rats. Hypertension 1993; 21:50-55.
13. 13 Lee RM, Berecek KH, Tsoporis J, McKenzie R, Triggle CR. Prevention of hypertension and vascular changes by captopril treatment. Hypertension 1991; 17:141-150.
14. 14 Wyss JM, Roysommuti S, King K, Kadisha I, Regan CP, Berecek K. Salt-induced hypertension in normotensive spontaneously hypertensive rats. Hypertension 1994; 23:791-796.
15. 15 Henry R, Casto R, Printz MP. Diurnal cardiovascular patterns in spontaneously hypertensive and Wistar-Kyoto rats. Hypertension 1990; 16:422-428.
16. 16 Lemmer B, Mattes A, Bohm M. Ganten D. Circadian blood pressure variation in transgenic hypertensive rats. Hypertension 1993; 22:97-101.
17. 17 Calhoun DA, Zhu S, Wyss JM, Oparil S. Diurnal blood pressure variation and dietary NaCl in spontaneously hypertensive rats. Hypertension 1994; 24:1-7.
18. 18 Harrap SB, Van der Merwe WM, Griffin SA, Macpherson F, Lever AF. Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 1990; 16:603-614.
19. 19 Winer BJ. Statistical principle in experimental design. 2nd edn. New York, New York: McGraw-Hill Book Co; 1971.
20. 20 Essig J, Belz GG, Wellstein A. The assessment of ACE activity in man following angiotensin challenges: a comparison of cilazapril, captopril and enalapril. Br J Clin Pharmacol 1989; 27 (suppl 2):217S-223S.
21. 21 Forslund T, Tikkanen I, Fyhrquist F. Decrease of serum angiotensin converting enzyme activity after discontinuation of captopril treatment. Acta Pharm Toxicol 1983; 53:78-80.
22. 22 Janssen BJ, Tyssen CM, Struyker-Boudier HA. Modification of circadian blood pressure and heart rate variability by five different antihypertensive agents in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1991; 17:494-503.
23. 23 van den Buuse M. Circadian rhythms of blood pressure, heart rate, and locomotor activity in spontaneously hypertensive rats as measured with radio-telemetry. Physiol Behav 1994; 55:783-787.
24. 26 Zhang L, Edwards DG, Berecek KH. Effects of early captopril treatment and its removal on plasma angiotensin converting enzyme (ACE) activity and arginine vasopressin in hypertensive rats (SHR) and normotensive rats (WKY). Clin Exp Hypertens 1996; 18:210-226.
25. 25 Campbell DJ. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor Type 1 antagonists. Clin Exp Pharmacol Physiol 1996; 22:S125-S131.
26. 26 Hilbert P, Lindpaintner K, Beckmann JS, Serikawa T, Soubrier F, Dubay C, et al. Chromosomal mapping of two genetic loci associated with blood-pressure regulation in hereditary hypertensive rats. Nature 1991; 353:521-529.
27. 27 Jacob HJ, Lindpaintner K, Lincoln SE, Kusumi K, Bunker RK, Mao YP, et al. Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell 1991; 67:213-224.
28. 28 Boutroy MJ, Vert P, Hurault de Ligny B, Miton A. Captopril administration in pregnancy impairs fetal angiotensin converting enzyme activity and neonatal adaptation. Lancet 1984; 2:935-936.
29. 29 Stevenson KM, Gibson KJ, Lumbers ER. Effects of losartan on the cardiovascular system, renal haemodynamics and function and lung liquid flow in fetal sheep. Clin Exp Pharmacol Physiol 1996; 23:125-133.
30. 30 Gohlke P, Bunning P, Unger T. Distribution and metabolism of angiotensin I and II in the blood vessel wall. Hypertension 1992; 20:151-157.
31. 31 Wu JN, Edwards D, Berecek KH. Changes in renal angiotensin II receptors in spontaneously hypertensive rats by early treatment with the angiotensin-converting enzyme inhibitor captopril. Hypertension 1994; 23:819-822.
32. 32 Swords BH, Wyss JM, Berecek KH. Central vasopressin receptors are upregulated by deoxycorticosterone acetate. Brain Res 1991; 559:10-16.
33. 33 Wilson KM, Magargal W, Berecek KH. Long-term captopril treatment. Angiotensin II receptors and responses. Hypertension 1988; 11:148-152.
34. 34 Leenen FHH, Klement G. Dietary sodium restriction and blood pressure response to sympathetic blockade in young vs. adolescent spontaneously hypertensive rats. Can J Physiol Pharmacol 1990; 68:46-50.
35. 35 Wyss JM, Mozaffari MS, Roysommuti S. Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats. J Hypertens 1995; 13:1037-1042.
36. 36 Oparil S, Chen YF, Berecek KH, Calhoun DA, Wyss JM. The role of the central nervous system in hypertension. In: Laraght JH, Brenner BM (editors): Hypertension: pathophysiology, diagnosis and management. 2nd edn. New York, New York: Raven Press; 1995. pp. 713-740.